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ABSTRACT 
 
Rationale: One measure of protein glycosylation (GlycA) has been reported to predict higher 
cardiovascular risk by reflecting inflammatory pathways  
 
Objective: To assess the role of a comprehensive panel of immunoglobulin (IgG) glycosylation traits on 
traditional risk factors for cardiovascular disease and on presence of subclinical atherosclerosis in addition 
to GlycA. 
 
Methods and Results: We measured 76 IgG glycosylation traits in 2970 women (age range 40-79 years) 
from the TwinsUK cohort and correlated it to their estimated 10-year atherosclerotic cardiovascular disease 
(ASCVD) risk score and their carotid and femoral plaque measured by ultrasound imaging. Eight IgG 
glycan traits are associated with the 10-year ASCVD risk score after adjusting for multiple tests and for 
individual risk factors – 5 with increased risk and 3 with decreased risk. These glycans replicated in 967 
women from ORCADES cohort, six of them were also associated in 845 men. A linear combination of IgG 
glycans and GlycA is also associated with presence of carotid (OR[95%CI]=1.55 [1.25;1.93], P=7.5X10-5) 
and femoral (OR[95%CI]==1.32[1.06;1.64], P=0.01) plaque in a subset of women with atherosclerosis data 
after adjustment for traditional risk factors. One specific glycosylation trait, GP18 was negatively correlated 
with VLDL and triglyceride levels in serum and with presence of carotid plaque (OR[95%CI] = 
0.60[0.50;0.71], P = 5x10-4). 
 
Conclusions: We find molecular pathways linking IgG to arterial lesion formation. Glycosylation traits are 
independently associated with subclinical atherosclerosis. One specific trait related to the sialylated N-
glycan is negatively correlated with CVD risk, VLDL and triglyceride serum levels and presence of carotid 
plaque.  
 
Keywords:  
IgG glycans, cardiovascular risk, atherosclerotic plaque, cardiovascular research, atherosclerosis.  
 
Nonstandard Abbreviations and Acronyms: 
 
ASCVD  atherosclerotic cardiovascular disease risk 
BMI   body mass index 
CVD   cardiovascular disease 
DZ   dizygotic twin  
FRS   Framingham Risk Score 
GlcNAc   N-acetylglucosamine 
IgG   immunoglobulin G 
MZ   monozygotic twin 
SBP   systolic blood pressure 
T2D   type 2 diabetes 
TC   total cholesterol 
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INTRODUCTION 
 
Cardiovascular diseases (CVDs) are the first cause of morbidity and mortality in Western 
countries1. In addition, the improvement of treatment and the reduction of case fatality are consistently 
increasing the prevalence of people who are at risk for recurring events and/or cardiac decompensation2. 
Many, often co-occurring, risk factors, have been identified and account for most of the CVD burden3 and 
different validated algorithms have been developed to estimate the individual risk of developing specific 
CVD events4-6. 
 
The 10-year atherosclerotic cardiovascular disease (ASCVD)7 risk score is a gender and race specific single 
multivariable risk assessment tool used to estimate the 10-year CVD risk of an individual that has replaced 
clinically the Framingham-10 years cardiovascular risk score (FRS)8. It is based on the age, sex, ethnicity, 
total and HDL cholesterol, systolic blood pressure, smoking status, use of blood pressure lowering 
medications, and the presence of type 2 diabetes (T2D). Data on subclinical atherosclerosis, presence of 
atherosclerotic plaques in carotid and femoral arteries, used in combination with traditional risk factors, 
provides additional information about the presence of coronary lesion9 and the risk of myocardial infarction, 
stroke, and CVD mortality10-13. Glycosylation is the most abundant and diverse form of post-transcriptional 
modification which participates in every physiological process14. Protein glycosylation is driven by specific 
enzymes and the complex carbohydrates (glycans) attached to, for example, immunoglobulins, have a 
specific regulatory role and result in differences in immune function15, 16. An altered protein glycosylation 
pattern has been described as a significant event that occurs during the transition from healthy to diseased 
tissue14, 17. This type of protein glycosylation is related to disease development in many syndromes such as 
congenital disorders of glycosylation, cancer, inflammatory bowel diseases, renal disease, rheumatoid 
arthritis, chronic obstructive pulmonary disease and AIDS18. Some of the most important interactions 
between the immune system and pathogens are mediated by protein-glycan interactions, and it has been 
shown that alterations of the glycosylation of immunoglobulin G (IgG), the most abundant immunoglobulin 
in circulation, have direct impact on its inflammatory properties16. Different IgG glycosylation profiles may 
provide an at risk phenotype to the developing of CVD since inflammation is known to play a crucial rule 
in CVD development19. A study of 27941 participants of the Women's Health Study, has previously shown 
that GlycA, a biomarker of plasma protein glycan N‐acetyl methyl groups (located on specific glycan 
branches of particular plasma proteins mainly α1acid glycoprotein, haptoglobin, α1antitrypsin, 
α1antichymotrypsin, and transferrin) is related to incident CVD17 which remained significant, when 
adjusting for traditional risk factors and for C-reactive protein levels17. GlycA, as a measure of protein 
glycosylation, has also been found to correlate with longitudinal risk of CVD, and mortality in various 
cohort studies (reviewed in 20) . However, besides GlycA, a large number of protein glycosylation traits can 
be measured21, 22. We hypothesized that these traits may reveal important information on the relationship 
between protein glycosylation, traditional risk factors and subclinical atherosclerosis. 
 
The aim of this study is to investigate the role of 76 IgG glycosylation traits in the risk of CVD 
measured with the 10-year ASCVD risk score7 by analyzing the IgG glycome composition in a large 
population based female cohort from the UK (TwinsUK). We then replicated the significant results in an 
independent sample from the ORCADES cohort. Finally, we investigate the association between the 
replicated glycan traits associated with CVD risk and presence of carotid and femoral atherosclerotic 
plaques in a subset of female individuals from the TwinsUK cohort.  
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METHODS 
 
The TwinsUK data that support the findings of this study are publicly available upon request on the 
department website (http://www.twinsuk.ac.uk/data-access/accessmanagement/). ITo access the 
ORCADES data, please email jim.wilson @ed.ac.uk. 
 
Discovery cohort. 
 Study subjects were individuals enrolled in the TwinsUK registry, a national register of adult twins23. In 
this study we analyzed data from 2970 females, 40 to 79 years old and without CVD. They had glycomics 
data available and the 10-year ASCVD risk score. The study was approved by St. Thomas’ Hospital 
Research Ethics Committee, and all twins provided informed written consent.  
 
Replication cohort. 
The replication sample was drawn from the Orkney Complex Disease Study (ORCADES). ORCADES is 
a family-based, cross-sectional study that seeks to identify genetic factors influencing cardiovascular and 
other disease risk in the isolated archipelago of the Orkney Isles in northern Scotland24. 2078 participants 
aged 16-100 years were recruited between 2005 and 2011, all of them having at least two Orcadian 
grandparents. Fasting blood samples were collected and many health-related phenotypes and environmental 
exposures were measured in each individual. Here we included 967 females with glycomics data available 
and the 10-year ASCVD risk score. All participants gave written informed consent and the study was 
approved by Research Ethics Committees in Orkney and Aberdeen. 
 
In addition to the replication carried out in women, we further validated our results in 189 men from 
TwinsUK and 656 men from ORCADES. 
 
Phenotype definitions. 
Data relevant to the present study include, BMI (body weight in kilograms divided by the square of height 
in square meters), T2D (defined as fasting glucose ≥7 mmol/L or physician’s letter confirming diagnosis), 
smoking (defined as current smoker, non smoker), treated and untreated systolic blood pressure (SBP), total 
and HDL cholesterol and insulin. Fasting insulin levels were measured using the same methods as 
previously described25. The homeostasis model assessment-estimated insulin resistance (HOMA-IR) was 
calculated multiplying overnight fasting plasma insulin (FPI) by overnight fasting plasma glucose (FPG), 
then dividing by the constant 22.5, i.e. HOMA-IR = (FPI×FPG)/22.515. The ASCVD risk score is an 
algorithm used to estimate the 10-year cardiovascular risk of an individual using the individual’s gender, 
ethnicity, age, smoking status, cholesterol levels, blood pressure and diabetes status7. The individual risk 
of CVD was estimated using the 10-year ASCVD risk score7 .  
 
Femoral and carotid plaque: Left and right carotid and femoral arteries were visualized with B-mode 
ultrasound (Siemens CV70, Siemens, Erlangen, Germany, with 13-MHz vascular probe) as previously 
described26. Briefly, arterial walls were examined for plaque in the common carotids, carotid bifurcations, 
origins of the internal and external carotid arteries, common femoral arteries, femoral bifurcations, and the 
origins of the superficial and deep femoral arteries. Plaque was defined in the longitudinal view as focal 
widening and protrusion into the lumen of ≥1.5-mm thickness relative to neighboring areas and confirmed 
in transverse view and it was graded according to echogenicity.  
 
Analysis of IgG glycans. 
IgG glycans were measured by Genos Ltd as previously described27, 28. Briefly, the IgG was isolated using 
protein G monolithic plates (BIA Separations, Ajdovščina, Slovenia). Dried IgG was denatured with 1.33 
% SDS (w/v) and N-glycans were released by digestion with PNGase F (ProZyme, Hayward, CA). After 
deglycosylation, N-glycans were labelled with 2- aminobenzamide fluorescent dye.  
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Free label and reducing agent were removed from the samples using hydrophilic interaction 
chromatography–solid-phase extraction.  
  
Fluorescently labelled N-glycans were separated by hydrophilic interaction chromatography on a Waters 
Acquity UPLC instrument (Waters, Milford, MA). Data processing was performed using an automatic 
processing method with a traditional integration algorithm after which each chromatogram was manually 
corrected to maintain the same intervals of integration for all the samples. The chromatograms were all 
separated in the same manner into 24 peaks and the amount of glycans in each peak was expressed as 
percentage of total integrated area. In addition to 24 directly measured glycan structures, 52 derived traits 
were calculated which is a maximal number of traits we were able to calculate. These derived traits average 
particular glycosylation features (galactosylation, fucosylation, bisecting N-acetylglucosamine (GlcNAc) 
and sialylation) (see Online Table I). The derived glycan traits are calculated from directly measured 
glycans and therefore their measurement error is smaller (at least the random error) 27.  
 
Lipoprotein profiling and glycoprotein by Nuclear Magnetic Resonance. 
Gycoprotein (GlycA), lipoproteins and triglycerides were measured by Nightingale Health (previously 
known as Brainshake Ltd, Finland, https://www.brainshake.fi/) from fasting serum samples using 500Mhz 
proton nuclear magnetic resonance spectroscopy as previously described 29.  
 
Statistical analysis. 
Statistical analysis was carried out using Stata version 12 and R version 3.3.3. 
 
Glycans were global normalised and log transformed due to right-skewness of their distributions. In order 
to remove experimental biases, all measurements were adjusted for batch and run-day effects using ComBat 
(R-package sva). Derived glycan traits were calculated using normalized and batch-corrected glycan 
measurements (exponential of batch corrected measurements). All variables were centred and scaled to 
have standard deviation 1. Outliers (more than 6SD from the mean) were excluded from the analysis.  
 
In the discovery cohort, association analyses between the 10-year ASCVD risk score and glycan traits were 
performed using linear mixed models adjusting for age BMI, and family relatedness as random effect. We 
used a conservative Bonferroni correction to account for multiple testing assuming 76 independent tests 
thus giving a significant threshold of (P<6.5x10-4=0.05/76). The Bonferroni significant 10-year ASCVD 
risk score glycan association were replicated in 967 females from the ORCADES study.  
 
To adjust for kinship in the ORCADES cohort, the 10-year ASCVD risk score traits were set to their 
grammar+ residuals in GenABEL using the genomic relationship matrix and no other covariates. These 
residuals are suitable for analysis as an unrelated population30. These kinship adjusted  10-year ASCVD 
risk score traits were then taken forward using the same (fixed only) effect model as TwinsUK. We then 
combined the results using inverse variance fixed effect meta-analysis. 
 
Linear mixed model adjusting for covariates and family relatedness were then undertaken in the TwinsUK 
sample to determine the association between the identified glycan traits with the contributing factors of the 
10-year ASCVD risk score (ie. T2D, smoking, total and HDL cholesterol and SBP) as well as with HOMA.  
We also looked at the association between the identified glycan traits with carotid and femoral plaque in a 
subset of 1382 female individuals from TwinsUK with plaque measured. 
 
Finally, we created a glycan risk score in females from TwinsUK to assess the combined effects of all 
glycan traits identified. We fitted a logistic regression model for the significantly replicated glycans to a 
binary trait of high 10-year ASCVD risk score. For this we selected the top quintile (corresponding to 10-
year ASCVD risk score >5.2%) taking the z-scores of all the significant IgG glycans using both linear and 
quadratic terms and using a stepwise regression approach to account for the collinearities between glycan 
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traits. The proportion of the variance in the 10-year ASCVD risk score was then assessed in women from 
TwinsUK and in men and women from ORCADES. The GlycA measure was added to the glycans from 
the score and this IgG+GlycA was tested for association with carotid and femoral plaque adjusting for log 
10-year ASCVD risk score score. 
 
 
 
RESULTS 
 
Levels of 76 IgG glycans (24 directly measured and 52 derived traits) (Online Table I) were obtained in 
2970 females from the TwinsUK sample and in 967 females from the ORCADES cohort with the 
ACC/AHA ASCVD risk score available (age range: 40-79 years). The demographic characteristics of the 
study populations are presented in Table 1. A flowchart of the study design is presented in Figure 1. 
 
Table 1. Demographic characteristics of the study populations 
TwinsUK ORCADES 
Phenotype Mean(SD) Mean(SD) 
n 2970 967 
Female % 100% 100% 
Carotid plaque, yes:no 336:1046 NA 
Femoral plaque, yes:no 337:1036 NA 
Age 57.41(8.71) 53.7(15.11) 
10-year ASCVD Risk Score 4.85(5.43) 6.9(11.24) 
BMI 26.61(4.85) 27.5(3.98) 
DBP, mmHG 77.63(9.79) 72.67(9.23) 
HDL Cholesterol, mmol/l 1.56(0.43) 1.62(0.43) 
HOMA-IR 1(0.74) NA 
SBP, mmHG 126.02(15.83) 125.12(19.52) 
Current smokers, n(%) 251(8.45%) 66(6.812%) 
Total Cholesterol, mmol/l 5.63(1.20) 5.47(1.16) 
T2D, n(%) 79 (2.66%) 28(2.89) 
 
Discovery and replication in women.  
 
We first ran linear mixed models in the discovery sample adjusting for age, BMI and family 
relatedness. We controlled for multiple testing using Bonferroni correction (P<6.58x10-4 =0.05/76 glycan 
traits). This identified 46 glycan traits significantly associated with the 10-year ASCVD risk score; 25 
glycan traits were positively associated with the 10-year ASCVD risk score, while 21 were negatively 
associated (Online Table I). We then assessed whether these associations with the 10-year ASCVD risk 
score were robust by testing for association these 46 glycans in 967 females from the ORCADES study. 
Out of those, 24 glycan traits were nominally associated with the 10-year ASCVD risk score (p<0.05) in 
the replication cohort and 10 glycans were significantly associated the 10-year ASCVD risk score after 
adjusting for covariates and multiple testing using Bonferroni correction (P<0.05/46). We then combined 
the results using inverse variance fixed effect meta-analysis. (Figure 2).  
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Validation in men.  
 
We tested whether these results discovered in women and replicated in women were also associated 
in men. We find that 6 of the 10 glycans are also significantly associated in men when we meta-analyse 
IgG glycan data from ORCADES and TwinsUK (n=845. Online Table II, Online Figure I) 
 
Adjustment for risk factors in women.  
 
We investigated in TwinsUK women, the association of the 10 replicated glycan traits with HDL 
and total cholesterol, smoking, SBP, T2D and insulin resistance. While no associations were observed with 
T2D and SBP (Online Table III), at P<0.05, all the glycan traits were associated with HDL cholesterol, 9 
were associated with total cholesterol and 5 were associated with smoking, and 5 were associated with 
insulin resistance (Figure 3, Online Table III). After adjusting for the contributing risk factors (Figure 3, 
Online Table IV) we find that 8 of the associations always remain statistically significant. 
 
Association with subclinical atherosclerosis.  
 
We assessed in TwinsUK women the association between the glycan traits identified as associated 
with CVD risk after adjustment for individual risk factors and carotid and femoral plaque, which are well 
known markers of subclinical coronary atherosclerosis 9. We find that 3 of these 8 glycan traits are 
associated with femoral plaque (P<0.05) and 4 of them are associated with carotid plaque (P<0.05), 
indicating that indeed these glycan traits are related to atherosclerosis. All but one of these associations 
remained significant (P<0.05) after adjusting for smoking (Figure 3, Online Table V). 
 
GlycA NMR association with the ACC/AHA 10-year ASCVD risk score.  
 
Because a number of authors31-33 have shown the effect of NMR measured glycoprotein on 
cardiovascular mortality we then investigated the association between this marker (GlycA) and ASCVD 
risk score. We find that indeed circulating levels of GlycA are positively and significantly correlated with 
the 10-year ASCVD risk score (0.14(0.02), P= 8.49x10-15) in the TwinsUK cohort. Higher circulating levels 
of GlycA are also associated with a higher risk of developing both carotid (OR(SE)= 1.41(0.21) , P= 0.020 
and femoral (1.57(0.26), P=0.005) plaque .  
 
Correlation between GlycA and IgG glycans.  
 
The NMR measured GlycA shows a significant correlation with all the 8 glycan traits that are 
reproducibly associated with the 10-year ASCVD risk score (summarized in Online Table VI). However, 
the correlation is not very large explaining 6% of variation in any of the IgG CVD-associated glycan trait. 
IgG glycan associations with the 10-year ASCVD risk score are consistent if we further adjust for GlycA. 
Glycan score. To assess the combined effects of all glycan traits we fitted a logistic regression model of 
the 8 glycans (with and without GlycA) to the top quintile corresponding of the 10-year ASCVD risk score 
(>5.2%) to compute a linear glycan score in females form the TwinsUK cohort (were who have both UPLC 
and NMR measures). After stepwise regression the model fitted on standardized (mean zero, variance 1, 
i.e. z-scores) of the IgG glycan measures was IgG score:  
 
݈݋݃݅ݐ	ܲݎሺ10 െ ݕ݁ܽݎ	ܣܵܥܸܦ	ݎ݅ݏ݇	ݏܿ݋ݎ݁	 ൐ 5.2%ሻ~ െ 1.545 െ 0.583 ൈ ܩܲ14 െ 0.390 ൈ ܩܲ18
൅ 0.285 ൈ ܩܲ6݊ െ 0.140 ൈ ܩܲ9݊ 
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This linear combination was associated with log (10-year ASCVD risk score) in a linear regression 
with Beta(SE)=0.477 (0.0211), P=2.3 x 10-96 explaining 26.9% of the variance in log(10-year risk ASCVD 
score) in our data. This score was then tested for association with log(10-year ASCVD risk score) in 
ORCADES where it explained 54.6% of the variance in log(10-year ASCVD risk score) (Beta(SE)=0.412 
(0.012), P=5.1 x 10-168) in women and 39.5% of the variance in log (the 10-year risk ASCVD 
score)(Beta(SE)=0.443 (0.021), P=1.7 x 10-73) in men. 
 
We then adjusted for GlycA levels in TwinsUK (where the NMR measure was available) the role 
of this glycan score. Adjusting for GlycA resulted in an association for the IgG score with 
Beta(SE)=0.441(0.0211) P=4.4 x 10-84 and of Beta(SE)=0.193(0.023) P=5.5 x 10-16 for GlycA indicating a 
significant contribution for both the combined IgG glycans and NMR measure. 
 
We therefore computed a glycan score based on both IgG glycans plus GlycA. The model identified 
was  IgG+GlycA score:  
 
݈݋݃݅ݐ	ܲݎሺ10 െ ݕ݁ܽݎݏ	ܣܵܥܸܦ	ݎ݅ݏ݇	ݏܿ݋ݎ݁	 ൐ 5.2%ሻ~ െ 1.295 െ 0.278 ൈ ܩܲ14 െ 0.502 ൈ ܩܲ18
൅ 0.232 ൈ ܩܲ6݊ െ 0.184 ൈ ܩܲ9݊ ൅ 0.215 ൈ ܩ݈ݕܿܣ 
 
This measure is strongly associated with log (10-year ASCVD risk score) (Beta(SE)=0.571(0.023), 
P=2.1x10-110) and explains 30.1% of the variation in log(10-year ASCVD risk score) in the TwinsUK data. 
The distribution of this IgG+GlycA score for each of the five quintiles of the 10-year ASCVD risk score 
distribution is shown as box plots in Figure 4A. We proceeded to compare the association between this the 
glycan score and 10-year ASCVD risk score on subclinical atherosclerosis. The associations of the glycan 
score in individuals with carotid and femoral plaque are presented in Figures 4B and 4D, while the 
distribution of log(10-year ASCVD risk score) in the same individuals is depicted in Figures 4C and 4E.  
 
In quantitative terms, the association between the glycan score and carotid plaque – adjusting for 
the 10-year ASCVD risk score - is OR[95%CI] = 1.55[1.25;1.93]; P=7.5x10-5) whereas the 10-year ASCVD 
risk score (adjusted for the glycan score ) is associated with OR[95%CI] =1.83[1.45;2.30]; P=3.8x10-7. For 
femoral plaque, the association of the glycan score (adjusted for the 10-year ASCVD risk score) was 
OR[95%CI]=1.32[1.06,1.64]; P=0.01) and that of the 10-year ASCVD risk score (adjusted for glycan score) 
OR[95%CI]=2.33[1.83;2.98] P=1.1x10-11). Thus the glycan score contributes significantly to both measures 
of subclinical atherosclerosis in addition to the known CVD risk factors. 
 
GP18 and VLDL.  
 
One of the glycan traits, GP18 (FA2G2S1), is negatively associated with ASCVD risk score, total 
cholesterol and carotid plaque, however the association remains significant after adjusting for total 
cholesterol. We therefore investigated its relationship to other measures of lipoproteins and triglycerides 
using the Nightingale platform. This monosialylated glycan with core fucose is strongly negatively 
correlated with various measures of lipids and triglycerides, in particular with the concentration of VLDL 
and triglycerides in VLDL (Online Table VII). To illustrate the magnitude of the associations between 
carotid plaque and glycosylation traits the distribution of GP18 in individuals with and without carotid 
plaque is shown in Figure 5 side by side to the distribution of 10-year ASCVD risk score. 
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DISCUSSION 
 
In this study we report that there are significant and reproducible IgG glycan traits associations 
with cardiovascular risk in addition to the previously reported ones with one single measure of protein 
glycosylation (GlycA). After adjustment for individual risk factors, we identify 8 quantitative IgG glycan 
traits associated with the 10-year ASCVD risk score in women from two independent cohorts , 6 of which 
are also associated in men. Four of the glycan traits identified are also associated with presence of 
subclinical atherosclerosis after adjusting for all traditional risk factors (3 with both femoral and carotid 
plaque, and 1 with carotid plaque only) indicating that indeed these glycan traits are related to 
atherosclerosis. 
 
Several recent studies have used targeted metabolomics platforms to examine a glycan signal 
(referred to as GlycA) thought to identify the concentration of circulating protein-bound N-acetyl methyl 
groups of GlcNAc and N-acetylgalatosamine glycan moieties based on NMR measures33. One such study33 
demonstrated that this signal was associated with longitudinal risk of mortality related to both ASCVD and 
cancer34.  
 
In this study we have used the NMR GlycA measure as a positive control and find that, this measure 
of protein glycosylation previously reported to be associated with CVD mortality by Lawler et al33 is also 
strongly associated in our data. In addition, 8 of the glycan associations we report to be associated with 10-
year ASCVD risk score, remain significant after adjusting for individual risk factors indicating that they 
are independently contributing to CVD risk. This is line with literature data indicating that IgG glycans are 
only weakly related to the GlycA NMR signal 35. Importantly, we find that a linear combination of IgG 
glycans predicts a large proportion of the variance in 10-years ASCVD risk score both in men (39%) and 
women (26-54%) and that this is reproducible. 
 
When we combined the GlycA NMR measure into an IgG+GlycA score and we found that it was 
strongly associated with both femoral and carotid plaque in the TwinsUK cohort. The association with 
subclinical atherosclerosis of this measure remained statistically significant after adjustment for 10-year 
ASCVD risk score, in line with previous reports20 that measures of protein glycosylation contribute to 
cardiovascular risk in addition to traditional risk factors. It is of interest that the association between the 
IgG glycan traits and CVD-related study endpoints remain significant after adjusting for GlycA, suggesting 
incremental information is gained with the different measures of glycans. 
 
 It has been hypothesized20 that protein glycosylation may be capturing a combined measure of  
upstream inflammation related to risk of ASCVD. Recently there has been an emerging focus on 
reclassification of diseases based on common mechanisms of pathophysiology and away from traditional 
clinical manifestation-defined approaches36 . Our data, with more comprehensive measures of protein 
glycosylation, highlight the potential value of glycomics in identifying such pathways of disease, the 
reproducibility of results across different cohorts and the extent to which CVD risk can be captured by these 
measures. 
 
  We also report that some IgG glycans are associated with higher CVD risk and others associated 
with lower CVD risk. More precisely, glycans that contain exposed three GlcNAcs (GP6) or glycans that 
contain both bisecting GlcNAc and one sialic acid are positively associated with CVD risk, (consistent with 
the previous GlycA reports) while sialylated glycans without a bisecting GlcNAc are negatively associated. 
Increased levels of glycans with a bisecting GlcNAc are reported to associate with higher age while 
decreased levels were associated with longevity 37. Even though only non-galactosylated glycoforms with 
a bisecting GlcNAc were associated with familial longevity, our results show that association of bisecting 
GlcNAc and CVD risk is not dependent on the presence of other sugar residues27, 37; we found 
agalactosylated, monogalactosylated and sialylated N-glycans with a bisecting GlcNAc positively 
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associated with CVD risk. Besides ageing, increased levels of glycans with a core-fucose and bisecting 
GlcNAc are known to be present in serum of patients with type 2 diabetes 38, and most of these glycans are 
coming from IgG 39 thus reflecting the same traits connected with CVD risk in this study.  
 
Age, T2D and smoking are all factors included in the 10-year ASCVD cardiovascular risk score 
assessment and have a positive association with a bisecting GlcNAc. IgG glycosylation is able to modulate 
Fc receptor binding, and bisecting GlcNAc was shown to increase antibody-dependent cellular cytotoxicity 
(ADCC) mediated by binding of the antibody to the Fcγ-receptor 40. Glycan traits known to increase ADCC 
are involved in pro-inflammatory pathway and inflammation is known to be underlying mechanism of 
CVD’s development19.  
 
 While bisecting GlcNAc is related with pro-inflammatory activity of IgG and the aforementioned 
conditions, sialylation and core-fucosylation are consistently associated with anti-inflammatory activity 16, 
42. Indeed, a core-fucosylated digalactosylated monosialylated glycan, GP18 (also called FA2G2S1) , over 
all glycan traits remains strongly associated with the10-year ASCVD risk score after adjustment for the 
individual risk factors that constitute the ASCVD risk score. After further investigation, we found that this 
glycan structure is strongly negatively correlated with VLDL levels. VLDL itself is a risk factor for 
cardiovascular disease being associated with hypertriglyceridemia and dyslipidemia in general 43. 
Importantly defects in the cholesterol metabolism pathway (particularly in the generation of non-sterol 
isoprene compounds) lead to disturbances in the glycosylation of proteins. This suggests a functional link 
between cholesterol metabolism and protein glycosylation44. Moreover, in rabbits, IgG and VLDL were 
shown to contribute arterial lesions and that sialic acid plays a crucial role in the prevention of an arterial 
lesion formation 45; even though our work supports that connection, the complete picture is still missing. 
Therefore, further studies should be carried out focusing on the role of these glycosylated structures in 
predicting cardiovascular events, and in particular their interaction with VLDL. 
 
We note some study limitations. The results were discovered and replicated primarily in women, 
even though most of the results are also replicated in men. Second, the cross-sectional nature of our data 
does not allow us to draw conclusions as to whether the identified glycan traits are causative of CVD decline 
or merely correlated with it, although the results from these hypothesis generating findings are consistent 
with other less comprehensive measures of glycosylations where causative links between glycosylation and 
CVD outcomes have been shown 33 34. Third, the associations were discovered with the 10-year ASCVD 
risk score and not with actual CVD events.  We report that these associations were also validated with 
measures of subclinical atherosclerosis after adjusting for all the risk factors in the 10-year ACC/AHA risk 
score, aiming to show that glycan traits provide molecular information that was not present in the pooled 
risk equation and thus suggesting an important biological role for these post-translational IgG modifications 
 
In conclusion, our data point to separate pathways whereby immunoglobulin glycosylation may be 
related to cardiovascular risk, on the one hand, a large number of N-glycan traits related to core-fucose and 
bisecting GlcNAc are strongly associated with atherosclerotic plaque. 
 
On the other hand, one specific trait related to the sialylated N-glycan appears to be strongly 
negatively related to circulating VLDL and is supportive of a role of IgG glycosylation in VLDL 
metabolism and arterial lesion formation also in humans. 
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FIGURE LEGENDS 
 
Figure 1. Discovery: The role of glycan traits on cardiovascular risk estimates was tested on 3281 samples 
available. Having identified traits significantly associated with CVD risk, we replicated them first, in an 
independent cohort, validated them in men and then investigated whether any of these associations could 
be exclusively explained by any of the individual factors that constitute the ACC/AHA10-year ASCVD 
risk estimate. The traits that remained associated were then tested for association with presence of 
subclinical atherosclerosis adjusting for the potential confounders. A sub-analysis was performed for the 
IgG glycan GP18 which is strongly negatively correlated with VLDL. 
 
Figure 2. Glycan traits significantly associated with ACC/AHA 10-year ASCVD risk score in the 
discovery, replication and meta-analysis. Analyses adjusted by age, sex, BMI, family relatedness and 
multiple testing. 
 
Figure 3. Glycan traits and ACVD components. Each cell of the matrix contains the regression coefficient 
between one glycan trait and a component of the 10-year ASCVD risk score and the corresponding p value. 
The table is color coded by correlation according to the table legend (red for positive and blue for negative 
correlations). ASCVD =10 year ASCCVD risk score, SMK= smoking, HDL= HDL cholesterol, TC= total 
cholesterol, HOMA= insulin resistance, ASCVD _SMK = 10-year ASCVD risk score adjusted for covariates 
and smoking, ASCVD _HDL=10-year ASCVD risk score adjusted for covariates and HDL cholesterol, 
ASCVD_ TC = 10-year ASCVD risk score adjusted for covariates and total cholesterol, ASCVD_HOMA= 
10-year ASCVD risk score adjusted for covariates and insulin resistance, FEM = femoral plaque, FEM 
_SMK =femoral plaque adjusted for covariates and smoking, CAR =carotid plaque, CAR _SMK =carotid 
plaque adjusted for covariates and smoking. 
 
Figure 4. (A) Box plot showing the distribution of the glycan score in quintiles of the 10-year ASCVD 
risks core. (B) Box plot showing the distribution of the glycan (IgG +GlycA) score in individuals with and 
without carotid plaque. P-values and odds ratios (OR) from logistic regression adjusted for log (10-year 
ASCVD risk score) (C) Box plot showing the distribution of the log (10-yearASCVD risk score) in 
individuals with and without carotid plaque, OR and p-value adjusted for glycan score (D) Box plot showing 
the distribution of the glycan score in individuals with and without femoral plaque. P-value and OR adjusted 
for log (10-year ASCVD risk score) (E) Box plot showing the distribution of the log (10-year ASCVD risk 
score) in individuals with and without femoral plaque, OR and p-value adjusted for glycan score. 
 
Figure 5. (A) Boxplot showing the distribution of the IgG glycan trait GP18 in individuals with and without 
carotid plaque. The p-values shown are unadjusted and adjusted for circulating levels of VLDL (B) 
Correlation between circulating VLDL and GP18. (C) Distribution of VLDL in individuals with and 
without carotid plaque. The p-values shown are unadjusted and adjusted for levels of GP18. 
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NOVELTY AND SIGNIFICANCE 
 
What Is Already Known? 
 
 Sugar molecules can attach to proteins in a process called glycosylation, which plays an important 
role in regulating inflammation. 
 
 One of these proteins, GlycA, is involved with an increased risk of heart disease. 
 
 There are many different types of glycosylated proteins and overall, they constitute the "glycome". 
  
 
What New Information Does This Article Contribute? 
 
 We tested 76 glycosylated immunoglobulin measures for association with the risk of 
atherosclerosis. 
 
 Four of these measures, plus GlycA, were associated with cardiovascular risk and ultrasound 
measures of atherosclerosis, even after taking into account all other known cardiovascular risk 
factors.  
 
Glycosylation is the process by which sugar molecules are attached to proteins and it plays an important 
role in regulating inflammation. One measure of glycosylated protein is GlycA, which is associated with 
an increased risk of cardiovascular disease. However, there are many different types of glycosylated 
proteins and collectively they constitute the "glycome". Here, we provide a comprehensive overview of the 
“glycome” by measuring 76 glycosylated immunoglobulin or “glycans” plus GlycA in 845 men and 3937 
women from two independent cohorts. Six of the glycans tested were associated with the summary risk 
score of atherosclerotic disease. In addition to GlycA, 4 other glycans were also associated with measures 
of atherosclerosis, even after taking into account other known cardiovascular risk factors. A combination 
of  all  significant glycan factors showed stronger association with  atherosclerosis, possibly though 
summation of the total amount of inflammation, which contributes to the risk of cardiovascular disease. 
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Supplementary Material
OnlineTable I. Description of 24 quantitative IgG glycosylation traits and 52 derived trait and association between all tested glycans and derived 
traits with the 10-year ASCVD risk score in the discovery cohort. Analyses adjusted by age, BMI and family relatedness. Significance cut-off: P< 
6.58x10
-4 
        10-year ASCVD risk score 
GROUP Glycan DESCRIPTION* FORMULA* Beta(SE) P 
Total IgG glycans (neutral + 
charged) 
GP1 
The percentage of FA1 glycan 
in total  IgG glycans  GP1 / GP* 100 0.002(0.01) 8.46E-01 
GP2 
The percentage of A2 glycan 
in total  IgG glycans  GP2 / GP* 100 0.051(0.01) 3.45E-07 
GP4 
The percentage of FA2 glycan 
in total  IgG glycans  GP4 / GP* 100 -0.005(0.011) 6.36E-01 
GP5 
The percentage of M5 glycan 
in total  IgG glycans  GP5 / GP* 100 0.037(0.01) 1.53E-04 
GP6 
The percentage of FA2B 
glycan in total  IgG glycans  GP6 / GP* 100 0.072(0.011) 1.30E-10 
GP7 
The percentage of A2G1 
glycan in total  IgG glycans  GP7 / GP* 100 0.028(0.009) 2.52E-03 
GP8 
The percentage of FA2[6]G1 
glycan in total  IgG glycans  GP8 / GP* 100 -0.046(0.009) 8.06E-07 
GP9 
The percentage of FA2[3]G1 
glycan in total  IgG glycans  GP9 / GP* 100 -0.052(0.009) 1.76E-08 
GP10 
The percentage of 
FA2[6]BG1 glycan in total  
IgG glycans  GP10 / GP* 100 0.048(0.009) 1.93E-07 
GP11 
The percentage of 
FA2[3]BG1 glycan in total  
IgG glycans  GP11 / GP* 100 0.054(0.01) 3.42E-08 
GP12 
The percentage of A2G2 
glycan in total  IgG glycans  GP12 / GP* 100 0(0.01) 9.66E-01 
GP13 
The percentage of A2BG2 
glycan in total  IgG glycans  GP13 / GP* 100 -0.01(0.009) 2.80E-01 
GP14 
The percentage of FA2G2 
glycan in total  IgG glycans  GP14 / GP* 100 -0.063(0.012) 1.49E-07 
GP15 
The percentage of FA2BG2 
glycan in total  IgG glycans  GP15 / GP* 100 0.005(0.011) 6.35E-01 
GP16 
The percentage of FA2G1S1 
glycan in total  IgG glycans  GP16 / GP * 100 -0.049(0.009) 1.32E-07 
GP17 
The percentage of A2G2S1  
glycan in total  IgG glycans  GP17/ GP * 100 0.012(0.009) 1.84E-01 
GP18 
The percentage of FA2G2S1 
glycan in total  IgG glycans  GP18 / GP * 100 -0.077(0.012) 5.59E-11 
GP19 
The percentage of FA2BG2S1 
glycan in total  IgG glycans  GP19 / GP * 100 -0.013(0.009) 1.55E-01 
GP20+GP21   
(GP20+GP21)/GP * 
100 0.017(0.009) 6.23E-02 
GP22 
The percentage of A2BG2S2 
glycan in total  IgG glycans  GP22 / GP * 100 0.022(0.009) 8.87E-03 
GP23 
The percentage of FA2G2S2 
glycan in total  IgG glycans  GP23 / GP * 100 -0.071(0.01) 1.43E-13 
GP24 
The percentage of FA2BG2S2 
glycan in total  IgG glycans  GP24 / GP * 100 -0.003(0.009) 7.04E-01 
Total IgG glycans - derived 
parameters 
FGS/(FG+FGS) 
The percentage of sialylation 
of fucosylated galactosylated 
structures without bisecting 
GlcNAc in total IgG glycans 
SUM(GP16 + GP18 + 
GP23) / SUM(GP16 + 
GP18 + GP23 + GP8 
+ GP9 + GP14)* 100 -0.034(0.01) 5.36E-04 
FBGS/(FBG+FBGS) 
The percentage of sialylation 
of fucosylated galactosylated 
structures with bisecting 
GlcNAc in total IgG glycans 
SUM(GP19 + GP24) / 
SUM(GP19 + GP24 + 
GP10 + GP11 + 
GP15)* 100 -0.031(0.009) 4.26E-04 
FGS/(F+FG+FGS) 
The percentage of sialylation 
of all fucosylated structures 
without bisecting GlcNAc in 
total IgG glycans 
SUM(GP16 + GP18 + 
GP23) / SUM(GP16 + 
GP18 + GP23 + GP4 
+  GP8 + GP9 + 
GP14)* 100 -0.042(0.011) 1.31E-04 
FBGS/(FB+FBG+FBGS) 
The percentage of sialylation 
of all fucosylated structures 
with bisecting GlcNAc in total 
SUM(GP19 + GP24) / 
SUM(GP19 + GP24 + 
GP6 + GP10 + GP11 -0.042(0.009) 4.47E-06 
IgG glycans + GP15)* 100 
FG1S1/(FG1+FG1S1) 
The percentage of 
monosialylation of 
fucosylated 
monogalactosylated 
structures in total IgG glycans 
GP16 / SUM(GP16 + 
GP8 + GP9)* 100 -0.005(0.009) 5.89E-01 
FG2S1/(FG2+FG2S1+FG2S2) 
The percentage of 
monosialylation of 
fucosylated digalactosylated 
structures in total IgG glycans 
GP18 / SUM(GP18 + 
GP14 + GP23)* 100 -0.021(0.009) 1.93E-02 
FG2S2/(FG2+FG2S1+FG2S2) 
The percentage of 
disialylation of fucosylated 
digalactosylated structures in 
total IgG glycans 
GP23 / SUM(GP23 + 
GP14 + GP18)* 100 -0.027(0.009) 2.99E-03 
FBG2S1/(FBG2+FBG2S1+FB
G2S2) 
The percentage of 
monosialylation of 
fucosylated digalactosylated 
structures with bisecting 
GlcNAc in total IgG glycans 
GP19 / SUM(GP19 + 
GP15 + GP24)* 100 -0.018(0.009) 5.64E-02 
FBG2S2/(FBG2+FBG2S1+FB
G2S2) 
The percentage of 
disialylation of fucosylated 
digalactosylated structures 
with bisecting GlcNAc in total 
IgG glycans 
GP24 / SUM(GP24 + 
GP15 + GP19)* 100 -0.001(0.009) 9.00E-01 
F
total
S1/F
total
S2 
Ratio of all fucosylated (+/- 
bisecting GlyNAc) 
monosialylated and 
disialylated structures in total 
IgG glycans 
SUM(GP16 + GP18 + 
GP19) / SUM(GP23 + 
GP24) -0.009(0.009) 3.29E-01 
FS1/FS2 
Ratio of fucosylated (without 
bisecting GlcNAc) 
monosialylated  and 
disialylated structures in total 
IgG glycans 
SUM(GP16 + GP18) / 
GP23 0.028(0.009) 1.50E-03 
FBS1/FBS2 
Ratio of fucosylated (with 
bisecting GlcNAc) 
monosialylated  and 
disialylated structures in total 
IgG glycans GP19 / GP24 -0.01(0.009) 2.65E-01 
FBS
total
/FS
total
 
Ratio of all fucosylated 
sialylated structures with and 
without bisecting GlcNAc 
SUM(GP19 + GP24) / 
SUM(GP16 + GP18 + 
GP23) 0.053(0.01) 4.18E-07 
FBS1/FS1 
Ratio of  fucosylated 
monosialylated structures 
with and without bisecting 
GlcNAc 
GP19 / SUM(GP16 + 
GP18) 0.041(0.01) 6.08E-05 
FBS1/(FS1+FBS1) 
The incidence of bisecting 
GlcNAc in all fucosylated 
monosialylated structures in 
total IgG glycans 
GP19 / SUM(GP16 + 
GP18 + GP19) 0.042(0.01) 5.97E-05 
FBS2/FS2 
Ratio of fucosylated 
disialylated structures with 
and without bisecting GlcNAc GP24 / GP23 0.101(0.01) 9.48E-23 
FBS2/(FS2+FBS2) 
The incidence of bisecting 
GlcNAc in all fucosylated 
disialylated structures in total 
IgG glycans  
GP24 / SUM(GP23 + 
GP24) 0.101(0.011) 2.23E-21 
Neutral IgG glycans 
GP1
n
 
The percentage of FA1 glycan 
in total neutral IgG glycans 
(GP
n
) GP1 / GP
n
* 100 0.009(0.01) 3.48E-01 
GP2
n
 
The percentage of A2 glycan 
in total  neutral IgG glycans 
(GP
n
) GP2 / GP
n
* 100 0.055(0.01) 3.34E-08 
GP4
n
 
The percentage of FA2 glycan 
in total  neutral IgG glycans 
(GP
n
) GP4 / GP
n
* 100 0.007(0.012) 5.32E-01 
GP5
n
 
The percentage of M5 glycan 
in total  neutral IgG glycans 
(GP
n
) GP5 / GP
n
* 100 0.046(0.01) 2.01E-06 
GP6
n
 
The percentage of FA2B 
glycan in total  neutral IgG 
glycans (GP
n
) GP6 / GP
n
* 100 0.096(0.012) 7.93E-17 
GP7
n
 
The percentage of A2G1 
glycan in total  Ineutral IgG 
glycans (GP
n
) GP7 / GP
n
* 100 0.032(0.009) 5.28E-04 
GP8
n
 
The percentage of FA2[6]G1 
glycan in total neutral IgG 
glycans (GP
n
) GP8 / GP
n
* 100 -0.044(0.01) 4.31E-06 
GP9
n
 
The percentage of FA2[3]G1 
glycan in total  neutral IgG 
glycans (GP
n
) GP9 / GP
n
* 100 -0.047(0.009) 2.58E-07 
GP10
n
 
The percentage of 
FA2[6]BG1 glycan in total  
neutral IgG glycans (GP
n
) GP10 / GP
n
* 100 0.062(0.009) 1.99E-11 
GP11
n
 
The percentage of 
FA2[3]BG1 glycan in total  
neutral IgG glycans (GP
n
) GP11 / GP
n
* 100 0.067(0.01) 4.19E-12 
GP12
n
 
The percentage of A2G2 
glycan in total  neutral IgG 
glycans (GP
n
) GP12 / GP
n
* 100 0.006(0.01) 5.30E-01 
GP13
n
 
The percentage of A2BG2 
glycan in total  neutral IgG 
glycans (GP
n
) GP13 / GP
n
* 100 0.003(0.01) 7.79E-01 
GP14
n
 
The percentage of FA2G2 
glycan in total  neutral IgG 
glycans (GP
n
) GP14 / GP
n
* 100 -0.047(0.012) 9.50E-05 
GP15
n
 
The percentage of FA2BG2 
glycan in total  neutral IgG 
glycans (GP
n
) GP15 / GP
n
* 100 0.017(0.011) 1.14E-01 
Neutral IgG glycans - derived 
parameters 
G0
n
 
The percentage of 
agalactosylated structures in 
total neutral IgG glycans  SUM(GP1
n
: GP6
n
) 0.036(0.012) 3.07E-03 
G1
n
 The percentage of SUM(GP7
n
: GP11
n
) -0.026(0.009) 4.69E-03 
monogalactosylated 
structures in total neutral  
IgG glycans  
G2
n
 
The percentage of 
digalactosylated structures in 
total neutral IgG glycans  SUM(GP12
n
: GP15
n
) -0.037(0.012) 1.72E-03 
F
n total
 
The percentage of all 
fucosylated (+/- bisecting 
GlcNAc) structures in total 
neutral IgG glycans  
SUM(GP1
n
+ GP4
n
+ 
GP5
n
+ GP6
n
+ GP8
n
+ 
GP9
n
+ GP10
n
+ 
GP11
n
+ GP14
n
+ 
GP15
n
) -0.028(0.009) 1.55E-03 
FG0
n total
/G0
n
 
The percentage of 
fucosylation of 
agalactosylated structures  
SUM(GP1
n
+ GP4
n
+ 
GP5
n
+ GP6
n
) / G0
n 
* 
100 -0.038(0.008) 6.61E-06 
FG1
n total
/G1
n
 
The percentage of 
fucosylation of 
monogalactosylated 
structures  
SUM(GP8
n
+ GP9
n
+ 
GP10
n
+ GP11
n
) / G1
n 
* 100 -0.031(0.009) 4.04E-04 
FG2
n total 
/G2
n
 
The percentage of 
fucosylation of 
digalactosylated structures  
SUM(GP14
n
+ GP15) / 
G2
n 
* 100 -0.026(0.009) 3.56E-03 
F
n
 
The percentage of fucosylated 
(without bisecting GlcNAc) 
structures in total neutral IgG 
glycans  
SUM(GP1
n
+ GP4
n
+ 
GP5
n
+ GP8
n
+ GP9
n
+ 
GP14
n
) -0.084(0.009) 3.68E-19 
FG0
n
/G0
n
 
The percentage of 
fucosylation (without 
bisecting GlcNAc) of 
agalactosylated structures  
SUM(GP1
n
+ GP4
n
+ 
GP5
n
) / G0
n 
* 100 -0.074(0.009) 2.22E-16 
FG1
n
/G1
n
 
The percentage of 
fucosylation (without 
bisecting GlcNAc) of 
monogalactosylated 
structures  
SUM(GP8
n
+ GP9
n
) / 
G1
n 
* 100 -0.082(0.009) 1.60E-18 
FG2
n
/G2
n
 
The percentage of 
fucosylation (without 
bisecting GlcNAc) of 
digalactosylated structures  GP14
n
/ G2
n 
* 100 -0.058(0.01) 1.51E-09 
FB
n
 
The percentage of fucosylated 
(with bisecting GlcNAc) 
structures in total neutral IgG 
glycans  
SUM(GP6
n 
+ GP10
n 
+ 
GP11
n 
+ GP15
n
) 0.09(0.01) 7.75E-20 
FBG0
n
/G0
n
 
The percentage of 
fucosylation (with bisecting 
GlcNAc) of agalactosylated 
structures  GP6
n
/ G0
n 
* 100 0.073(0.009) 4.22E-15 
FBG1
n
/G1
n
 
The percentage of 
fucosylation (with bisecting 
GlcNAc) of 
monogalactosylated 
structures  
SUM(GP10
n 
+ GP11
n
) 
/ G1
n 
* 100 0.08(0.01) 5.72E-17 
FBG2
n
/G2
n
 
The percentage of 
fucosylation (with bisecting 
GlcNAc) of digalactosylated 
structures  GP15) / G2
n 
* 100 0.072(0.01) 1.90E-12 
FB
n
/F
n
 
Ratio of fucosylated structures 
with and without bisecting 
GlcNAc FB
n
/ F
n
 * 100 0.09(0.01) 3.70E-20 
FB
n
/F
n total
 
The incidence of bisecting 
GlcNAc in all fucosylated 
structures in total neutral IgG 
glycans  FB
n
/ F
n
 
total
 * 100 0.09(0.01) 6.23E-20 
F
n
/(B
n
 + FB
n
) 
Ratio of fucosylated non-
bisecting GlcNAc structures 
and all structures with 
bisecting GlcNAc F
n
/(GP13
n 
+ FB
n
 ) -0.089(0.01) 7.74E-20 
B
n
/(F
n
 + FB
n
) 
Ratio of structures with 
bisecting GlcNAc and all 
fucosylated structures (+/- 
GP13
n
/ (F
n
+ FB
n
 ) * 
1000 0.004(0.009) 6.61E-01 
bisecting GlcNAc) 
FBG2
n
/FG2
n
 
Ratio of fucosylated 
digalactosylated structures 
with and without bisecting 
GlcNAc GP15
n
/GP14
n
 0.074(0.01) 4.86E-13 
FBG2
n 
/(FG2
n
 + FBG2
n
 ) 
The incidence of bisecting 
GlcNAc in all fucosylated 
digalactosylated structures in 
total neutral IgG glycans  
GP15
n
/(GP14
n 
+ 
GP15
n
) * 100 0.074(0.01) 5.73E-13 
FG2
n
/(BG2
n
 + FBG2
n
) 
Ratio of fucosylated 
digalactosylated non-
bisecting GlcNAc structures 
and all digalactosylated 
structures with bisecting 
GlcNAc 
GP14
n
/(GP13
n 
+ 
GP15
n
) -0.074(0.01) 1.23E-12 
BG2
n
/(FG2
n
 + FBG2
n
) 
Ratio of digalactosylated 
structures with bisecting 
GlcNAc and all fucosylated 
digalactosylated structures 
(+/- bisecting GlcNAc) 
GP15
n
/(GP14
n 
+ 
GP15
n
) * 1000 0.038(0.01) 2.18E-04 
 
*Previously published in Lauc et al. 2013 
Online Table II. Descriptive characteristics of the male population included in the validation analysis. 
 TwinsUK ORCADES 
Phenotype Mean(SD) Mean(SD) 
n 189 656 
Males % 100% 100% 
Age 57.21(10.88) 54.51(14.76) 
10-years ASCVD Risk Score 11.04(9.29) 12.19(13.59) 
BMI 26.70(3.71) 28.03(5.51) 
DBP, mmHG 82.03(9.79) 72.67(9.23) 
HDL Cholesterol, mmol/l 1.24(0.35) 1.33(0.37) 
SBP, mmHG 133.19(16.13) 132.07(16.26) 
Current smokers,%  2.65% 8.52% 
Total Cholesterol, mmol/l 5.24(1.20) 5.32(1.12) 
T2D, % 0% 4.71% 
  
Online Table III. Glycan traits associated with the 10-years ASCVD risk score and their association with smoking, HDL and total cholesterol, systolic 
blood pressure, type 2 diabetes and insulin resistance adjusting for age, BMI and family relatedness in the discovery cohort. 
 ASCVD SMK HDL TC SBP T2D HOMA 
Glycan Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P 
GP6 0.07 
(0.01) 
1.30x10
-10
 0.52 
(0.08) 
2.08x10
-10
 -0.04 
(0.01) 
4.07x10
-6
 0.07 
(0.03) 
1.51x10
-2
 -0.13 
(0.34) 
7.01x10
-1
 0.18 
(0.14) 
1.90x10
-1
 0.06 
(0.02) 
9.63x10
-4
 
GP14 -0.06 
(0.01) 
1.49x10
-7
 -0.13 
(0.1) 
1.80x10
-1
 0.03 
(0.01) 
7.50x10
-4
 -0.15 
(0.03) 
9.48x10
-8
 -0.21 
(0.36) 
5.56x10
-1
 -0.11 
(0.19) 
5.71x10
-1
 -0.03 
(0.02) 
1.91x10
-1
 
GP18 -0.08 
(0.01) 
5.59x10
-11
 -0.19 
(0.09) 
4.71x10
-2
 0.05 
(0.01) 
8.92x10
-8
 -0.15 
(0.03) 
2.94x10
-8
 -0.32 
(0.35) 
3.55x10
-1
 -0.13 
(0.16) 
3.92x10
-1
 -0.05 
(0.02) 
4.20x10
-3
 
FGS/(F+FG+FGS) -0.04 
(0.01) 
1.31x10
-4
 -0.01 
(0.09) 
8.71x10
-1
 0.05 
(0.01) 
1.27x10
-8
 -0.06 
(0.03) 
2.10x10
-2
 -0.35 
(0.33) 
2.77x10
-1
 -0.01 
(0.14) 
9.40x10
-1
 -0.07 
(0.02) 
3.15x10
-5
 
FBStotal/FStotal 0.05 
(0.01) 
4.18x10
-7
 0.22 
(0.09) 
1.03x10
-2
 -0.03 
(0.01) 
1.31x10
-3
 0.08 
(0.02) 
8.22x10
-4
 -0.14 
(0.31) 
6.46x10
-1
 0.07 
(0.15) 
6.66x10
-1
 0.01 
(0.02) 
7.19x10
-1
 
FBS1/FS1 0.04 
(0.01) 
6.08x10
-5
 0.12 
(0.08) 
1.62x10
-1
 -0.03 
(0.01) 
4.25x10
-4
 0.07 
(0.02) 
3.56x10
-3
 -0.1 
(0.31) 
7.50x10
-1
 0.01 
(0.15) 
9.38x10
-1
 0.02 
(0.02) 
3.27x10
-1
 
FBS1/(FS1+FBS1) 0.04 
(0.01) 
5.97x10
-5
 0.11 
(0.08) 
1.76x10
-1
 -0.03 
(0.01) 
5.63x10
-4
 0.07 
(0.02) 
2.55x10
-3
 -0.11 
(0.31) 
7.24x10
-1
 0.01 
(0.16) 
9.31x10
-1
 0.02 
(0.02) 
3.36x10
-1
 
GP6n 0.1 
(0.01) 
7.93x10
-17
 0.73 
(0.09) 
3.33x10
-15
 -0.04 
(0.01) 
4.85x10
-5
 0.13 
(0.03) 
5.57x10
-6
 -0.24 
(0.35) 
4.99x10
-1
 0.28 
(0.16) 
7.94x10
-2
 0.04 
(0.02) 
3.19x10
-2
 
GP9n -0.05 
(0.01) 
2.58x10
-7
 -0.54 
(0.06) 
6.40x10
-18
 0.02 
(0.01) 
1.43x10
-2
 0.02 
(0.02) 
3.25x10
-1
 0.27 
(0.27) 
3.23x10
-1
 -0.18 
(0.12) 
1.23x10
-1
 -0.02 
(0.01) 
3.02x10
-1
 
GP14n -0.05 
(0.01) 
9.50x10
-5
 -0.01 
(0.1) 
9.31x10
-1
 0.04 
(0.01) 
2.03x10
-5
 -0.1 
(0.03) 
8.11x10
-4
 -0.29 
(0.36) 
4.24x10
-1
 -0.05 
(0.16) 
7.76x10
-1
 -0.05 
(0.02) 
6.75x10
-3
 
GlycA* 0.13 
(0.01) 9.34x10
-21
 
0.24 
(0.09) 9.39x10
-3
 
-0.09 
(0.01) 3.31x10
-14
 
0.23 
(0.03) 9.70x10
-12
 
1.06 
(0.42) 0.01 
0.55 
(0.17) 1.30x10
-3
 
0.13 
(0.02) 5.10x10
-13
 
ASCVD=10-year atherosclerotic cardiovascular disease risk score adjusting for age, BMI and family relatedness; SMK= smoking, HDL= HDL cholesterol, 
TC= total cholesterol,  SBP= systolic blood pressure; T2D=type 2 diabetes; HOMA=insulin resistance. *GlycA was measured in mmol/L by the NMR 
metabolomics provider Nightingale inc under the name GP. GlycA has been standardised to have mean 0 and SD 1. 
  
Online Table IV. Association of glycan traits with the 10-year ASCVD risk score overall and  adjusting for smoking, HDL cholesterol, total 
cholesterol and HOMA respectively in the discovery cohort. 
 
 ASCVD ASCVD_adj_SMK ASCVD_adj_HDL ASCVD_adj_TC ASCVD_adj_HOMA 
Glycan Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P Beta 
(SE) 
P 
GP6 0.07 
(0.01) 
1.30x10
-10
 0.05 
(0.01) 
4.68x10
-7
 0.05 
(0.01) 
4.58x10
-7
 0.06 
(0.01) 
4.54x10
-9
 0.05 
(0.01) 
1.57x10
-4
 
GP14 -0.06 
(0.01) 
1.49x10
-7
 -0.06 
(0.01) 
6.18x10
-9
 -0.05 
(0.01) 
1.39x10
-5
 -0.04 
(0.01) 
1.84x10
-4
  
-0.05 
(0.01) 
9.02x10
-4
 
GP18 -0.08 
(0.01) 
5.59x10
-11
 -0.07 
(0.01) 
1.86x10
-11
 -0.05 
(0.01) 
6.31x10
-7
 -0.06 
(0.01) 
4.03x10
-7
 -0.06 
(0.01) 
1.24x10
-5
 
FGS/(F+FG+FGS) -0.04 
(0.01) 
1.31x10
-4
 -0.04 
(0.01) 
2.96x10
-5
 -0.02 
(0.01) 
5.59x10
-2
 -0.03 
(0.01) 
1.11x10
-3
 -0.02 
(0.01) 
9.62x10
-2
 
FBStotal/FStotal 0.05 
(0.01) 
4.18x10
-7
 0.05 
(0.01) 
1.12x10
-6
 0.04 
(0.01) 
2.55x10
-5
 0.04 
(0.01) 
2.73x10
-5
 0.05 
(0.01) 
2.13x10
-5
 
FBS1/FS1 0.04 
(0.01) 
6.08x10
-5
 0.04 
(0.01) 
1.87x10
-5
 0.03 
(0.01) 
2.72x10
-3
 0.03 
(0.01) 
1.20x10
-3
 0.04 
(0.01) 
8.25x10
-4
 
FBS1/(FS1+FBS1) 0.04 
(0.01) 
5.97x10
-5
 0.04 
(0.01) 
1.56x10
-5
 0.03 
(0.01) 
2.43x10
-3
 0.03 
(0.01) 
1.34x10
-3
 0.04 
(0.01) 
1.01x10
-3
 
GP6n 0.1 
(0.01) 
7.93x10
-17
 0.07 
(0.01) 
5.69x10
-11
 0.08 
(0.01) 
2.90x10
-13
 0.08 
(0.01) 
6.75x10
-13
 0.08 
(0.01) 
7.35x10
-9
 
GP9n -0.05 
(0.01) 
2.58x10
-7
 -0.02 
(0.01) 
9.94x10
-3
 -0.04 
(0.01) 
6.14x10
-6
 -0.05 
(0.01) 
6.92x10
-9
 -0.05 
(0.01) 
2.30x10
-6
 
GP14n -0.05 
(0.01) 
9.50x10
-5
 -0.05 
(0.01) 
3.02x10
-6
 -0.03 
(0.01) 
1.08x10
-2
 -0.03 
(0.01) 
3.10x10
-3
 -0.02 
(0.01) 
9.85x10
-2
 
GlycA 0.13 
(0.01) 
9.34 x10
-21
 
0.11 
(0.01) 
1.19x10
-16
 
0.09 
(0.01) 
2.27x10
-11
 
0.11 
(0.01) 
4.35x10
-15
 
0.11 
(0.02) 
2.33x10
-12
 
ASCVD=10-year atherosclerotic cardiovascular disease risk score adjusting for age, BMI and family relatedness; ASCVD_adj_SMK= 10-years ASCVD 
score adjusting for age, BMI, family relatedness and smoking, ASCVD_adj_HDL= 10-years ASCVD scor adjusting for age, BMI, family relatedness and 
HDL cholesterol, ASCVD_adj_TC= 10-years ASCVD scor adjusting for age, BMI, family relatedness and total cholesterol,  ASCVD_adj_HOMA2IR= 10-
years ASCVD scor adjusting for age, BMI, family relatedness and HOMA2IR. Glycan traits in italics do not remain statistically significant after adjustment 
for individual risk factors.  *GlycA was measured in mmol/L by the NMR metabolomics provider Nightingale inc under the name GP. GlycA has been 
standardised to have mean 0 and SD 1. 
 
Online Table V. Glycan traits associated with the 10-year ASCVD risk score and their association with femoral and carotid plaque in TwinsUK 
females. 
 
Femoral plaque Femoral plaque adj SMK Carotid plaque Carotid plaque adj SMK 
Glycan Beta(SE) P Beta(SE) P Beta(SE) P Beta(SE) P 
GP6 0.387(0.152) 0.01 0.359(0.158) 0.02 0.467(0.154) 2.40x10
-3
 0.453(0.157) 3.92x10
-3
 
GP14 -0.174(0.165) 0.29 -0.177(0.166) 0.29 -0.213(0.155) 0.17 -0.221(0.156) 0.16 
GP18 -0.128(0.162) 0.43 -0.144(0.165) 0.38 -0.494(0.147) 7.70x10
-4
 -0.524(0.152) 5.81x10
-4
 
FBStotal/FStotal 0.021(0.149) 0.89 0.022(0.149) 0.89 0.173(0.133) 0.19 0.177(0.132) 0.18 
FBS1/FS1 -0.03(0.148) 0.84 -0.003(0.15) 0.98 0.123(0.127) 0.33 0.154(0.13) 0.23 
FBS1/(FS1+FBS1) -0.041(0.149) 0.78 -0.014(0.152) 0.93 0.12(0.13) 0.35 0.152(0.133) 0.25 
GP6n 0.48(0.154) 1.88x10
-3
 0.427(0.159) 0.01 0.39(0.152) 0.01 0.347(0.155) 0.03 
GP9n -0.252(0.128) 0.05 -0.211(0.129) 0.10 -0.297(0.119) 0.01 -0.264(0.121) 0.03 
GlycA* 0.317(0.105) 0.002 0.313(0.107) 0.003 0.194(0.099) 0.05 0.298(0.15) 0.049 
*GlycA was measured in mmol/L by the NMR metabolomics provider Nightingale inc under the name GP. GlycA has been standardised to have mean 0 and 
SD 1. 
 
 
 
 
 
Online Table VI. Pearson’s correlation and p-value between the 8 IgG glycans reproducibly  and the NMR GlycA measure in TwinsUK 
Pearson 
Correlations 
GlycA* GP6 GP14 GP18 FBStotal/ 
FStotal 
FBS1/FS1 FBS1/ 
(FS1+FBS1) 
GP6n GP9n 
GlycA 1         
GP6 0.21 
7.7x10
-18
 
1        
GP14 -0.22 
3.4x10
-20
 
-0.69 
2.5x10
-233
 
1       
GP18 -0.21 
2.5x10
-18
 
-0.74 
5.4x10
-284
 
0.87 
<10
-300
 
1      
FBStotal/FStotal 0.17 
4.5x10
-12
 
0.50 
8.1x10
-103
 
-0.73 
4.8x10
-273
 
-0.76 
<10
-300
 
1     
FBS1/FS1 0.16 
2.2x10
-11
 
0.50 
4.1x10
-102
 
-0.70 
7.4x10
-244
 
-0.77 
<10
-300
 
0.97 
<10
-300
 
1    
FBS1/(FS1+FBS1) 0.16 
2.2x10
-11
 
0.50 
7.0x10
-104
 
-0.70 
2.1x10
-244
 
-0.77 
<10
-300
 
0.97 
<10
-300
 
0.99 
<10
-300
 
1   
GP6n 0.20 
9.8x10
-17
 
0.94 
<10
-300
 
-0.78 
<10
-300
 
-0.76 
<10
-300
 
0.55 
3.2x10
-128
 
0.51 
3.7x10
-111
 
0.52 
9.6x10
-113
 
1  
GP9n -0.06 
2.4x10
-2
 
-0.30 
8.0x10
-36
 
0.1369 
2.7x10
-8
 
0.111 
2.0x10
-5
 
-0.10 
2.1x10
-5
 
-0.08 
1.1x10
-3
 
-0.08 
2.1x10
-3
 
-0.34 
2.2x10
-45
 
1 
*GlycA was measured in mmol/L by the NMR metabolomics provider Nightingale inc under the name GP. GlycA has been standardised to have mean 0 and 
SD 1. 
 
  
Online Table VII. Association between GP18 and various measures of cholesterol, lipoproteins and triglycerides in serum from TwinsUK females  
Lipid trait Beta SE P 
Apolipoprotein A-I 0.069 0.055 2.09x10
-1
 
Apolipoprotein B -0.148 0.052 4.86x10
-3
 
Concentration of chylomicrons and extremely large VLDL 
particles 
-0.210 0.053 9.73x10
-5
 
Concentration of IDL particles -0.070 0.052 1.80x10
-1
 
Concentration of large HDL particles 0.149 0.054 5.70x10
-3
 
Concentration of large LDL particles -0.083 0.053 1.19x10
-1
 
Concentration of large VLDL particles -0.226 0.053 2.29x10
-5
 
Concentration of medium HDL particles 0.093 0.050 6.36x10
-2
 
Concentration of medium LDL particles -0.082 0.054 1.30x10
-1
 
Concentration of medium VLDL particles -0.228 0.052 1.56x10
-5
 
Concentration of small LDL particles -0.089 0.053 9.23x10
-2
 
Concentration of small VLDL particles -0.213 0.050 2.25x10
-5
 
Concentration of very large HDL particles 0.095 0.055 8.66x10
-2
 
Concentration of very large VLDL particles -0.224 0.054 3.49x10
-5
 
Concentration of very small VLDL particles -0.149 0.049 2.64x10
-3
 
Remnant cholesterol (non-HDL, non-LDL -cholesterol) -0.138 0.049 5.16x10
-3
 
Sphingomyelins -0.045 0.058 4.41x10
-1
 
Triglycerides in chylomicrons and extremely large VLDL -0.209 0.053 9.24x10
-5
 
Triglycerides in HDL -0.079 0.045 8.26x10
-2
 
Triglycerides in IDL -0.086 0.046 6.48x10
-2
 
Triglycerides in large HDL 0.092 0.047 4.93x10
-2
 
Triglycerides in large LDL -0.060 0.047 2.07x10
-1
 
Triglycerides in large VLDL -0.223 0.052 1.85x10
-5
 
Triglycerides in LDL -0.063 0.049 1.97x10
-1
 
Triglycerides in medium HDL -0.093 0.048 5.38x10
-2
 
Triglycerides in medium LDL -0.038 0.050 4.51x10
-1
 
Triglycerides in medium VLDL -0.227 0.051 1.31x10
-5
 
Triglycerides in small LDL -0.106 0.048 2.94x10
-2
 
Triglycerides in small VLDL -0.213 0.050 2.81x10
-5
 
Triglycerides in very large HDL -0.048 0.050 3.37x10
-1
 
Triglycerides in very large VLDL -0.223 0.053 2.71x10
-5
 
Triglycerides in very small VLDL -0.165 0.048 6.04x10
-4
 
Triglycerides in VLDL -0.197 0.048 5.10x10
-5
 
 
  
Online  Figure I. Glycan traits significantly associated with 10-years ASCVD risk in females 
and validation in males.  
 
 
